Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour

Aoki, Yoichi; Kasamatsu, Takahiro; Ochiai, Kazunori; Takano, Masashi; Watanabe, Yoh; Kikkawa, Fumitaka; Takeshima, Nobuhiro; Hatae, Masayuki; Yokota, Harushige; Saito, Toshiaki; Yaegashi, Nobuo; Kobayashi, Hiroaki; Baba, Tsukasa; Kudoh, Shoji; Saito, Tsuyoshi; Sakuragi, Noriaki; Sumi, Toshiyuki; Kamura, Toshiharu; Yoshikawa, Hiroyuki

doi:10.1016/j.ejca.2014.12.004

Cited by 27 publications

(19 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Low-dose intensity and compliance with the administration schedule have been reported to affect prognosis; thus, the treatment should not be changed or delayed due to temporary side effects. 21 In MOGCT patients, in addition to a desire for cure, a desire to become pregnant in the future may improve treatment compliance, as shown in the present study.…”

Section: Commentsupporting

confidence: 62%

Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study

Tamauchi

Kajiyama

Yoshihara

et al. 2018

American Journal of Obstetrics and Gynecology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Commentsupporting

confidence: 62%

Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study

Tamauchi

Kajiyama

Yoshihara

et al. 2018

American Journal of Obstetrics and Gynecology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Serum alpha-fetoprotein (AFP) is a useful marker for YST, informative for monitoring response to chemotherapy and tumor recurrence [ 6 , 7 ]. Treatment modalities for MOGCTs are based on those for testicular germ cell tumors (TGCTs) [ 8 , 9 ], including surgery, possibly followed by platinum-based chemotherapy [ 10 – 13 ].…”

Section: Introductionmentioning

confidence: 99%

Napabucasin overcomes cisplatin resistance in ovarian germ cell tumor-derived cell line by inhibiting cancer stemness

et al. 2020

View full text Add to dashboard Cite

Background: Cisplatin resistance of ovarian yolk sac tumors (oYST) is a clinical challenge due to dismal patient prognosis, even though the disease is extremely rare. We investigated potential association between cisplatin resistance and cancer stem cell (CSC) markers in chemoresistant oYST cells and targeting strategies to overcome resistance in oYST. Methods: Chemoresistant cells were derived from chemosensitive human oYST cells by cultivation in cisplatin in vitro. Derivative cells were characterized by chemoresistance, functional assays, flow cytometry, gene expression and protein arrays focused on CSC markers. RNAseq, methylation and microRNA profiling were performed. Quail chorioallantoic membranes (CAM) with implanted oYST cells were used to analyze the micro-tumor extent and interconnection with the CAM. Tumorigenicity in vivo was determined on immunodeficient mouse model. Chemoresistant cells were treated by inhibitors intefering with the CSC properties to examine the chemosensitization to cisplatin. Results: Long-term cisplatin exposure resulted in seven-fold higher IC 50 value in resistant cells, cross-resistance to oxaliplatin and carboplatin, and increased migratory capacity, invasiveness and tumorigenicity, associated with hypomethylation of differentially methylated genes/promotors. Resistant cells exhibited increased expression of prominin-1 (CD133), ATP binding cassette subfamily G member 2 (ABCG2), aldehyde dehydrogenase 3 isoform A1 (ALDH3A1), correlating with reduced gene and promoter methylation, as well as increased expression of ALDH1A3 and higher overall ALDH enzymatic activity, rendering them cross-resistant to DEAB, disulfiram and napabucasin. Salinomycin and tunicamycin were significantly more toxic to resistant cells. Pretreatment with napabucasin resensitized the cells to cisplatin and reduced their tumorigenicity in vivo. Conclusions: The novel chemoresistant cells represent unique model of refractory oYST. CSC markers are associated with cisplatin resistance being possible targets in chemorefractory oYST.

show abstract

“…In cases of early-stage yolk-sac tumors (stage I) surgery patients (with chemotherapy limited only to cases of relapse) showed higher recurrence rates but no difference in overall survival, saving 77 % of patients from chemotherapy [ 122 ]. However, in cases of higher-stage yolk-sac tumors standard-dose BEP chemotherapy has been associated with favorable overall survival rates and no apparent compromise of fertility rates [ 113 , 123 ]. In early-stage pure dysgerminoma also, chemotherapy is only recommended in cases of relapse, according to several authors [ 114 , 115 ].…”

Section: Introductionmentioning

confidence: 99%

Fertility preservation in women with cervical, endometrial or ovarian cancers

Feichtinger

Rodriguez‐Wallberg

2016

gynaecol oncol res pract

View full text Add to dashboard Cite

BackgroundAlthough cancer in general affects an aged population, a significant number of women develop cancer at childbearing age. Long-term survival rates after gynecological cancer, especially in young patients are increasing and all quality-of-life aspects, including preservation of fertility have become of major relevance.OutcomesSurgical techniques aimed at sparing reproductive organs and preserving fertility have been developed for women presenting with gynecological cancer found at early stages. Indications for fertility-sparing surgery are in general restricted to women presenting with a well-differentiated low-grade tumor in its early stages or with low malignant potential. Up to now, use of fertility-sparing techniques in well-selected patients has not been shown to affect overall survival negatively and fertility outcomes reported have been favorable. Still larger amounts of data and longer follow-up periods are needed. Several current fertility-sparing cancer treatments may result in sub-fertility and in those cases assisted reproductive techniques are indicated. Overall quality of life has been satisfactory in cancer patients after fertility-sparing surgery.ConclusionsFertility-sparing surgery is a viable tool to enable gynecological cancer patients of young age to fulfill their family building without impairment of oncological outcome. Cancer patients of reproductive age should undergo fertility counseling to analyze this sensitive subject. Further studies are needed to investigate the role of fertility-sparing treatment and combined adjuvant therapy in higher-grade cancers.

show abstract

Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour

Cited by 27 publications

References 28 publications

Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study

Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study

Napabucasin overcomes cisplatin resistance in ovarian germ cell tumor-derived cell line by inhibiting cancer stemness

Fertility preservation in women with cervical, endometrial or ovarian cancers

Contact Info

Product

Resources

About